|
|
 |
|
Viewing report
|
|
|
|
GPC Biotech AG: Premium Company Profile
Datamonitor, Jan 2008, Pages: 45
GPC Biotech (GPC), founded in 1997, has a business model relied on two pillars, as a service provider for preclinical research and as a product company with its own development pipeline. Later, the company changed its focus by developing a platform of base technologies, LeadCode, through collaborations with pharmaceutical partners and through the support of its own drug development projects.
Scope of this title
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights of this title
GPC is a biopharmaceutical company focused on discovery, development and commercialization of new anticancer drugs, Cell Cycle Inhibitors and antibodies against MHC class II-positive tumor cells. Its most advanced product candidate satraplatin is currently in SPARC Phase III trial, for the treatment of hormone-refractory prostate cancer.
The companys second lead product candidate, 1D09C3, is in Phase I clinical trials and is a monoclonal antibody indicated for the treatment of relapsed/refractory B-cell lymphomas, such as Hodgkins and non-Hodgkins lymphomas and chronic lymphocytic leukemia.
The companys total revenues increased at a CAGR of 1.3% during 2002-2006, from $27.6 million to $29.1 million. This represents an absolute total growth of +$1.5 million during the historical period. The companys biggest contributor to revenue growth during 2002-2006 was license, collaboration and other revenues.
Key reasons to purchase this title
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
GPC Biotech AG - Financial and Strategic Analysis Review
GPC Biotech AG
GPC Participacoes SA
GPC Biotech AG and Agennix, Inc. Merger Call - GPC Biotech AG, - Earnings Transcript
MorphoSys AG: Premium Company Profile
Overseas Shipholding Group Inc Oil & Gas Company Report: Profile Includes Information about Companys Assets across the Oil & Gas Value Chain
Hospira, Inc. Medical Equipment Company Report: Medical Device Company Analysis Covering key Information Relating to Company Market Share by Sector and Country, Financial, SWOT and Value Chain Analysis
Golar LNG Limited Oil & Gas Company Report: Profile Includes Information about Companys Assets across the Oil & Gas Value Chain
Grupa LOTOS S.A. Oil & Gas Company Report: Profile Includes Information about Companys Assets across the Oil & Gas Value Chain
Poland 2002-2006: Midyear Summary
Vector Limited Oil & Gas Company Report: Profile Includes Information about Companys Assets across the Oil & Gas Value Chain
Sunoco, Inc. Oil & Gas Company Report: Profile Includes Information about Companys Assets across the Oil & Gas Value Chain
|
|
|
|
